

## Curriculum Vitae

Name **Dr Stephen Gerard O'BRIEN**  
Date of Birth 18<sup>th</sup> February 1964  
Nationality British  
GMC registration no. 3240090  
JCHMT accreditation 17<sup>th</sup> June 1997  
Current position Senior Lecturer in Haematology, University of Newcastle  
Honorary Consultant Haematologist, Royal Victoria Infirmary,  
Newcastle. Appointed March 1999.  
Work address Department of Haematology, University of Newcastle, Royal  
Victoria Infirmary, Newcastle NE1 4LP  
Telephone +44 191 282 0568  
Fax +44 191 222 5524  
Email s.g.o'brien@ncl.ac.uk

### 1. Education

1974-1981 William Hulme's Grammar School, Manchester  
1981-1987 University of Manchester Medical School  
*Honours in Pathology and Community Medicine, Distinction in  
Surgery, Mark Lascelles Surgery Prize at finals*  
1984-1985 Intercalated Honours BSc Pathology  
1986 Elective period at Stanford University Medical School, Palo Alto,  
California, USA.

### 2. Qualifications

BSc (Hons) Pathology	University of Manchester	July 1985
MB ChB	University of Manchester	July 1987
FRCP (UK)	Royal College of Physicians	November 1990
MRCPath	Royal College of Pathologists	March 1997
PhD	Imperial College, University of London	May 1998

### 3. Previous appointments

Dates	Position	Qualifications obtained
1987-91	House jobs (Withington & Manchester Royal Infirmary), SHO in Medicine at MRI.	MRCP
1991-93	Registrar. Department of Haematology, Hammersmith Hospital, London	MRCPath part 1
1993-96	Research Fellow (Honorary SR). LRF Adult Leukaemia Unit, Hammersmith Hospital (Imperial College, London. (Prof JM Goldman)	PhD
1996-99	Clinical Lecturer (Honorary SR) Department of Haematology, University of Wales College of Medicine	MRCPath part 2

## 4. Selected recent publications

Luger SM, **O'Brien SG**, Ratajczak J, Ratajczak MZ, Mick R, Stadtmauer EA, Nowell PC, Goldman JM, Gewirtz AM. Oligodeoxynucleotide-mediated inhibition of c-myc expression in autografted bone marrow: a pilot study. *Blood* 2002; 99: 1150-58.

Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Goldman JM, **O'Brien SG**, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Huriez C, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo R, Baccarani M, Morra M, Zoellner U, Gathmann I, Druker BJ. Hematological and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia. *New Eng J Med* 2002; 346: 645-52.

**O'Brien SG**, Vieira SAD, Connors S, Bown N, Chang J, Capdeville R and Melo JV. Transient response to imatinib mesylate in a patient with the ETV6-ABL, t(9;12) translocation. *Blood* 2002; 99: 3465-67.

Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller C, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MWN, Fischer T, **O'Brien SG**, Stone R, Gambacorti-Passerini C, Russell N, Reiffers J, Shea T, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ. Imatinib mesylate induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. *Blood* 2002; 99: 3530-39.

Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger M, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, **O'Brien SG**. A phase II study of imatinib mesylate (Glivec™) in patients with relapsed or refractory Philadelphia chromosome-positive acute leukemias. *Blood* 2002; 100: 1965-71.

Takayama N, Sato N, **O'Brien SG**, Ikeda Y, Okamoto S. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. *Br J Haematol* 2002; 119:106-8.

**O'Brien SG**, Rule SA. BCSH position paper on imatinib mesylate in chronic myeloid leukaemia. *Br J Haematol* 2002; 119: 268-72.

Rule SA, **O'Brien SG**, Crossman LC. Managing cutaneous reactions to imatinib therapy. *Blood* 2002; 100: 3434-5.

Druker BJ, **O'Brien SG**, Cortes J, Radich J. Chronic myelogenous leukaemia. *Hematology (Am Soc Hematol Educ Programme)* 2002: 111-35.

**O'Brien SG**, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F, Cornelissen J, Fischer T, Hochhaus A, Hughes T, Lechner K, Mahon FX, Nielsen J, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman J, Kantarjian H, Taylor K, Verhoef G, Bolton A, Capdeville R and Druker B on behalf of the IRIS Investigators. Imatinib compared with Interferon and low-dose cytarabine for newly-diagnosed chronic phase chronic myeloid leukaemia. *New Eng J Med* 2003; 348: 994-1004.

Practical management of patients with chronic myeloid leukaemia receiving imatinib. Deininger MWN, **O'Brien SG**, Ford J, Druker BJ. *J Clin Oncol* 2003; 21: 1637-47.


Hahn E, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, **O'Brien SG**, Dobrez DG, Hensley ML, Cella D. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon-alpha plus low-dose Ara-C: Results from the IRIS Study. *J Clin Oncol*. 2003; 21: 2138-2146.

**O'Brien SG**, Meinhardt P, Bond E, Beck J, Peng B, Dutreix C, Mehring G, Milosavljev S, Capdeville R, Huber C, Fischer T. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome 3A4 substrate, in patients with chronic myeloid leukemia. *Br J Cancer* 2002; **89**: 1855-9.

Imatinib in patients with newly-diagnosed chronic phase-chronic myeloid leukaemia. **O'Brien SG**, Deininger MWN. *Seminars in Hematology* 2003; **40**: 26-30.

Marin D, Marktel S, Bua M, Szydlo R, Franceschino A, Nathan I, Foot N, Crawley C, Na Nakorn T, Olavarria E, Lennard A, Neylon A, **O'Brien SG**, Goldman JM & Apperley JF. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. *Leukemia* 2003; **17**:1448-1453.

Irving JA, **O'Brien SG**, Lennard AL, Minto L, Lin F, Hall, A. G. Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to imatinib. *Clinical Chemistry*; 50: 1233-1237.



29<sup>th</sup> October 2007